wild-type EHEB and the p53 mutated MEC-2 leukemic cells as well as cells of a representative B-CLL patient (Pt.) sample were exposed to Ibrutinib (10 μM) and RG7112 (10 μM) used either alone or in combination for 48 hours. Cell viability was calculated as percentage with respect to the control untreated cultures (set to 100% for each cell culture). Data are reported as the mean±SD of results from at least three independent experiments. The asterisk indicates p<0.05 respect to single treatments.
